Glucagon-like peptide-1 (GLP-1) Biological Role in Patients of Type 2 Diabetes and Metabolic Syndrome

Jump To References Section

Authors

  • Mohammedziyad Abu Awad

DOI:

https://doi.org/10.21048/ijnd.2019.56.2.20967

Keywords:

Cardiovascular diseases, metabolic syndrome, glucose, food intake

Abstract

Type2 diabetes is estimated to affect 380 million people worldwide in 2025. Patients of this disease are at increased risk of cardiovascular diseases (CVD).The CVD risk is greater when diabetic patients have metabolic syndrome. Thus, the management of metabolic syndrome and CVD is crucial for diabetic patient's life progress. GLP-1 has positive biological influences on glucose metabolism control by inhibiting glucagon secretion, enhancing insulin secretion and protecting the effects of cells. GLP-1 was also found to have other positive influences including weight loss, appetite sensation and food intake. These are important factors in metabolic disturbances control and CVD management. The paper reviewed several studies regarding the GLP-1 positive concerns. In conclusion, the paper supports the modern proposal of GLP-1 RAs as a first line therapy in initially diagnosed type 2 diabetes patients.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

2019-04-03

How to Cite

Awad, M. A. (2019). Glucagon-like peptide-1 (GLP-1) Biological Role in Patients of Type 2 Diabetes and Metabolic Syndrome. The Indian Journal of Nutrition and Dietetics, 56(2), 227–229. https://doi.org/10.21048/ijnd.2019.56.2.20967

Issue

Volume 56, Issue 2, April - June 2019

Section

Short Communication

License

All the articles published in IJND are distributed under a creative commons license. The journal allows the author(s) to hold the copyright of their work (all usages allowed except for commercial purpose).

Please contact us at editor@informaticsglobal.com for permissions related to commercial use of the article(s).

Crossref
Scopus
Google Scholar
Europe PMC
Received 2018-04-23
Accepted 2019-02-07
Published 2019-04-03

 

References

Yoo, S., Yang, E.J., Lee, S.A. and Koh, G. Post meal increment in intact glucagon-like peptide 1 level, but not intact glucose-dependent insulinotropic polypeptide levels, is inversely associated with metabolic syndrome in patients with type 2 diabetes. Endocrine Res., 2018, 43, 47-54.

Bodnaruc, A. M., Prud'homme, D., Blanchet, R. and Giroux, I. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr. Metabol., 2016, 13, 92.

Dar, S., Tahrani, A.A. and Piya, M.K. The role of GLP 1 receptor agonists as weight loss agents in patients with and without type 2 diabetes. Practical Diab., 2015, 32, 297.

Htike, Z.Z., Zaccardi, F., Papamargaritis, D., Webb, D.R., Khunti, K. and Davies, M.J.Efficacy and safety of glucagon like peptide 1 receptor agonists in type 2 diabetes: A systematic review and mixed treatment comparison analysis. Diabetes, Obesity and Metabol., 2017, 19, 524-536.

AL-Domi, H. and Mahmud, I. Anti-obesity effect of peripheral exendin-4 and/or exercise in high-fat diet-induced obese C57bl/6 mice. Pak. J. Nutr., 2016, 15, 379.

Abdul-Ghani, M. and DeFronzo, R.A. Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace Metformin in the type 2 diabetes algorithm.Diabetes care, 2017, 40, 1121-1127.

Nauck, M.A. and Meier, J.J. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.The Lancet Diab. Endocrinol., 2016, 4, 525-536.

Holst, J.J., Gribble, F., Horowitz, M. and Rayner, C.K. Roles of the gut in glucose homeostasis. Diabetes Care, 2016, 39, 884-892.

Campbell, J.E. and Drucker, D.J. Pharmacology, physiology and mechanisms of incretin hormone action. Cell Metabol., 2013, 17, 819-837.